• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»ArteraAI Prostate Test

What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology

By Pallavi Madhiraju on May 29, 2026   Medical Devices & Diagnostics  

What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology

Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.

Recent Posts

  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
  • Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes